Generic Name and Formulations:
Tiagabine HCl 2mg, 4mg, 12mg, 16mg; tabs.
Indications for GABITRIL:
Adjunct in partial seizures.
Take with food. Use lower doses and titrate slower if not on concomitant enzyme-inducing drug(s). 12–18yrs: 4mg once daily for 1 week; may increase to 8mg/day in 2 divided doses for 1 week; then may increase by 4–8mg weekly to clinical response or up to 32mg/day in 2–4 divided doses. ≥18yrs: 4mg once daily for 1 week; may increase by 4–8mg weekly to clinical response or up to 56mg/day in 2–4 divided doses.
Hepatic impairment: reduce dose. Reduce dose or discontinue if generalized weakness occurs. Adjust dose if spike and wave discharges on EEG with cognitive or neuropsychiatric events occur. Discontinue and evaluate if seizures develop in nonepileptic patients during therapy. Suicidal tendencies (monitor). Avoid abrupt cessation. Elderly. Pregnancy (Cat.C). Nursing mothers.
GABA reuptake inhibitor.
CNS depression may be potentiated by alcohol, triazolam, other CNS depressants. Tiagabine levels reduced by enzyme inducers (eg, phenytoin, carbamazepine, primidone, phenobarbital), St. John's wort. May interact with valproate (monitor). May affect or be affected by highly protein bound drugs.
Dizziness, asthenia, somnolence, fatigue, GI upset/pain, nervousness, tremor, abdominal pain, concentration difficulties, dysphasia, confusion, other CNS effects, serious rash; possible long-term ophthalmologic effects.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline